Barcelona

• Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) Ended
  2023-505494-32-00 5 2018-10-15 Focal segmental glomerulosclerosis (FSGS)
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv … Ended
  2023-508955-37-00 5 2018-10-10 Moderate to severe atopic dermatitis
• Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in HER2 Positive Advanced Gastric or GEJ Adenocarcinoma Ended
  2023-508253-98-00 5 2018-10-05 Gastric or gastroesophageal junction (GEJ) adenocarcinoma
• Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Chemotherapy plus Paclitaxel and Bevacizumab in Carcinoma of the Cervi … Ended
  2024-514179-17-00 5 2018-10-02 Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cerv
• A Study to Assess Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small … Ended
  2023-508083-30-00 4 2018-07-19 Non-small cell lung cancer (NSCLC)
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended
  2023-506641-35-00 4 2018-07-09 Relapsed/Refractory Mantle Cell Lymphoma
• A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati … Ended
  2023-508472-11-00 5 2018-06-13 Patients with early breast cancer
• A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment … Ended
  2023-506564-14-00 1 2018-05-16 Relapsed and refractory multiple myeloma (RRMM)
• A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Non-Small Cell Lu … Ended
  2023-504038-23-00 9 2018-05-10 Metastatic non-small cell lung cancer (NSCLC)
• PROLONGSTEM is a long term follow-up study of all the patients who have received at least one infusion of HepaStem Ended
  2022-500251-22-00 4 2018-04-12 This study will include all patients having received at least one infu
• A Trial to Determine The Safety and Efficacy of CC-92480 Alone and When Combined With Dexamethasone in People Who Have Myeloma That is Not R … Ended
  2023-508727-12-00 4 2018-04-12 Relapsed and refractory multiple myeloma (RRMM)
• A Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemothe … Ended
  2023-504209-35-00 5 2018-04-04 Early-Stage Resectable Non-small cell lung cancer (NSCLC)
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• A Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Urothelial Cancer Ended
  2023-510296-56-00 5 2018-03-26 Advanced Urothelial Cancer
• A study to find out if an investigational product, called LN-145 (also called tumor infiltrating lymphocytes) is an effective and safe treat … Ended
  2024-510634-41-00 4 2018-02-22 Recurrent, metastatic, or persistent Cervical Carcinoma
• A study to assess the safety and anti-tumor activity of T cell therapy in subjects with advanced liver cancer or any other AFP expressing tu … Ended
  2024-514437-37-00 1 2018-02-22 Advanced Hepatocellular Carcinoma (HCC) that is not amenable to transp
• A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line trea … Ended
  2024-512015-47-00 5 2018-01-09 Histologically or cytologically-confirmed Recurrent or Metastatic Head
• Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Canc … Ended
  2024-513167-68-00 5 2017-11-29 endometrial cancer
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Duc … Ended
  2024-511271-15-00 9 2017-11-23 Pancreatic ductal adenocarcinoma (PDAC)
• A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) o … Ended
  2023-507143-11-00 5 2017-11-08 Precancerous form of blood cancer in the bone marrow
• A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated, … Ended
  2023-509711-83-00 5 2017-10-27 Advanced or Metastatic Renal Cell Carcinoma
• A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV … Ended
  2023-508757-75-00 5 2017-09-18 Stage IV Non-Small Cell Lung Cancer (NSCLC)
• Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM14 Administered Intravenously to Patients with Advanced Solid … Ended
  2024-511916-25-00 7 2017-09-04 Advanced Solid Tumors
• A Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in previously untreated Subjects with Acute Myeloid Leukemia who ar … Ended
  2024-513631-25-00 5 2017-08-17 Acute Myeloid Leukemia

Showing 3,289–3,312 of 3,391 trials